The US Department of Justice issued subpoenas to two makers of generic pharmaceuticals last week, sparking an investigation into the industry and its competition. Now, report say, the case is already growing.
Generic drug makers Lannett and Impax Laboratories both confirmed they were contacted by the DOJ as part of a probe into their relationships with rivals. Impax added that the subpoena demanded one of its sales representatives to hand over documents and offer testimony about communication with rival drug makers.
The DOJ also revealed details of its investigation in a filing with the Securities and Exchange Commission.
Reports released earlier this year found that the price of some generic drugs charged to pharmacies has nearly doubled in the last year – leading prices for consumers to, in some cases, triple.
Connecticut’s Attorney General launched an investigation earlier this year into price hikes for congestive heart failure drug digoxin, a drug made by both Lannett and Impax, say reports.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI